The nutritional impact of CD19‐targeted CAR‐T therapy versus BEAM chemotherapy for adult patients with lymphoma

Abstract

AbstractBackgroundChimeric antigen receptor T (CAR‐T) cell therapy is a novel therapy demonstrating durable remissions in patients with refractory or relapsing non‐Hodgkin's B‐cell lymphoma. Maintaining a patient's nutritional status has been demonstrated to improve outcomes in cancer treatment. However, no studies have investigated how CAR‐T therapy affects nutritional status, nor compared its impact with other cancer treatments for this patient group. The primary aim of the present study was to investigate the effect of CAR‐T therapy on the prevalence of nutrition impact symptoms (NIS) and nutritional status within 30 days post‐treatment of patients with lymphoma compared to a conditioning regimen for autologous haematopoetic stem cell transplant (carmustine/BCNU, Etoposide, cytarabine/Ara‐C, Melphalan [BEAM] auto‐haematopoetic stem cell transplant [HSCT]).MethodsClinical notes of patients with lymphoma who underwent either CAR‐T therapy or BEAM auto‐HSCT between 2018 and 2021 were reviewed. Data extracted included body weight measurements and NIS, including decreased appetite, nausea, vomiting, diarrhoea, constipation, mucositis, cytokine release syndrome (CRS) and neurotoxicity at baseline and 30 ± 7 days post‐treatment.ResultsIn total, 129 adults with lymphoma (n = 88 CAR‐T vs. n = 41 BEAM) were included. Nutritional status was assessed in both groups at baseline prior to treatment. Mean absolute weight change was significantly different between groups (3.05 kg in CAR‐T, −5.9 kg in BEAM, p ≤ 0.001). This was also significant when weight loss was categorised into percentage weight loss (p = 0.01). CAR‐T patients experienced a significantly lower prevalence of decreased appetite (52.3% vs. 97.6%) nausea (25% vs. 78%,) vomiting (10.2% vs. 53.7%), diarrhoea (43.2% vs. 96.7%) and mucositis (5.7% vs. 75.6%) combined across all levels of severity compared to BEAM chemotherapy (all p ≤ 0.01). CRS and neurotoxicity, which are specific side effects of CAR‐T therapy, were moderately positively associated with weight loss.ConclusionsWeight loss, percentage weight loss and NIS were significantly reduced in CAR‐T compared to BEAM treatment. However, patients who experienced neurotoxicity during treatment did have significant weight loss.